Lilly reports mixed data for CGRP mAb in cluster headache

Eli Lilly and Co. (NYSE:LLY) said galcanezumab met the primary endpoint in a Phase III trial to prevent episodic cluster headache but missed in a Phase III trial in chronic cluster headache. Lilly said it is working with global regulatory authorities to determine a path forward based on the episodic cluster headache data.

The humanized mAb targeting calcitonin gene-related peptide (CGRP) is under FDA review to prevent migraine in adults. Lilly expects a decision next quarter...